Skip to main content

Andrew Berchuck, MD

Andrew Berchuck, MD
James M. Ingram Professor of Gynecologic Oncology
Campus Mail: 25171 Morris Bldg, Durham, NC 27710
Phone: (919) 684-3765
Email: berch001@mc.duke.edu

Dr. Andrew Berchuck is Director of the Duke Division of Gynecologic Oncology and holds the James M. Ingram Distinguished Professorship. He is a practicing oncologist who is actively involved in the surgical and chemotherapy management of women with ovarian, endometrial and lower genital tract cancers. This includes minimally invasive laparoscopic surgical approaches. He also has developed a research program that focuses on the molecular-genetic alterations involved in malignant transformation of the ovarian and endometrial epithelium. He has published over 300 peer-reviewed papers in these areas. The objectives of his research include 1) identification of ovarian cancer susceptibility polymorphisms through a population-based case-control molecular epidemiologic study, and 2) use of genomic approaches  to elucidate the molecular heterogenetity of ovarian cancer. Thirty fellows and residents have worked in his lab, several of whom are now funded investigators. His research efforts have been recognized nationally and he has received awards for best oral presentation at the annual meetings of both the Society of Gynecologic Oncology and the International Gynecologic Cancer Society. Dr. Berchuck was awarded the Barbara Thomason Ovarian Cancer Research Professorship by the American Cancer Society in 2006. He has served as editor of several books in the field including Principles and Practice of Gynecologic Oncology. Dr. Berchuck also has a major commitment to national activities, and was President of the Society of Gynecologic Oncology in 2008. He served as chair of the scientific advisory committee of the Ovarian Cancer Research Fund (http://www.ocrf.org) in New York City. Finally, he is also head of the steering committee of the international Ovarian Cancer Association Consortium (OCAC), a group of 50 case-control studies that are working together to identify ovarian cancer susceptibility polymorphisms (www.srl.cam.ac.uk/consortia/ocac/index.html).

Education and Training

  • M.D., Case Western Reserve University, 1980

Research

Dr Berchuck is interested in the molecular pathogenesis of ovarian and endometrial cancer. 

View Publications

Publications

Berchuck, A, Kuchenbaecker, K, Ramus, SJ, Tyrer, JP, Gayther, SA, Pharoah, PDP, Antoniou, AC, and Chenevix-Trench, G. "IDENTIFICATION OF SIX NOVEL, COMMON VARIANT GENETIC SUSCEPTIBILITY LOCI FOR INVASIVE EPITHELIAL OVARIAN CANCER." INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER 24, no. 9 (November 2014): 13-13.

Scholars@Duke

Ness, R, Pearce, CPC, Stram, DSD, Berchuck, ABA, Pike, MPM, Pharoah, PPP, and OCAC, . "LIFETIME RISK OF OVARIAN CANCER BASED ON ENDOMETRIOSIS AND OTHER RISK FACTORS." INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER 24, no. 9 (November 2014): 441-442.

Scholars@Duke

Berchuck, A, Witkowski, L, Hasselblatt, M, Wallace, A, Clarke, BA, and Foulkes, WD. "PROPHYLACTIC OOPHORECTOMY FOR HEREDITARY SMALL-CELL CARCINOMA OF THE OVARY, HYPERCALCEMIC TYPE." INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER 24, no. 9 (November 2014): 961-962.

Scholars@Duke

Kelemen, LE, Tyrer, J, Phelan, CM, Ramus, SJ, Berchuck, A, Gayther, SA, Goode, EL, Pearce, CL, Schildkraut, JM, Chenevix-Trench, G, Monteiro, AN, Goodman, MT, Sellers, TA, and Pharoah, PP. "Abstract 3283: GWAS identifies risk variants for mucinous ovarian carcinoma." October 1, 2014.

Full Text

Stevens, EV, Whitaker, R, Guinet, A, Chang, C-Y, Grenier, C, Marks, J, McDonnell, DP, Murphy, SK, Berchuck, A, and Gaillard, S. "Abstract 4570: Role of ERRalpha in ovarian cancer." October 1, 2014.

Full Text

Permuth-Wey, J, Chen, YA, Chen, Z, Berchuck, A, Chenevix-Trench, G, Doherty, J, Gayther, S, Goode, EL, Iversen, E, Monteiro, AN, Pearce, L, Pharoah, PD, Phelan, CM, Pirie, A, Ramus, S, Rossing, MA, and Schildkraut, JM. "Abstract 946: Exome genotyping array identifies rare and low-frequency variants that may be associated with ovarian cancer risk." October 1, 2014.

Full Text

Witkowski, L, Carrot-Zhang, J, Albrecht, S, Hamel, N, Tomiak, E, Grynspan, D, Saloustros, E, Gilpin, C, Silva-Smith, R, Plourde, F, Rivera, B, Castellsagué, E, Wu, M, Fahiminiya, S, Nadaf, J, Saskin, A, Arseneault, M, Karabakhtsian, RG, Reilly, EA, Ueland, FR, Margiolaki, A, Pavlakis, K, Castellino, SM, Lamovec, J, Roth, LM, Ulbright, TM, Bender, T, Longy, M, Berchuck, A, Tischkowitz, M, Siebert, R, Nagel, I, Georgoulias, V, Stewart, CJ, McCluggage, G, Arseneau, J, Clarke, BA, and Riazalhosseini, Y et al. "Abstract LB-89: Germ-line and somatic SMARCA4 mutations characterize small cell carcinoma of the ovary, hypercalcemic type." October 1, 2014.

Full Text

Kelemen, LE, Terry, KL, Goodman, MT, Webb, PM, Bandera, EV, McGuire, V, Rossing, MA, Wang, Q, Dicks, E, Tyrer, JP, Song, H, Kupryjanczyk, J, Dansonka-Mieszkowska, A, Plisiecka-Halasa, J, Timorek, A, Menon, U, Gentry-Maharaj, A, Gayther, SA, Ramus, SJ, Narod, SA, Risch, HA, McLaughlin, JR, Siddiqui, N, Glasspool, R, Paul, J, Carty, K, Gronwald, J, Lubiński, J, Jakubowska, A, Cybulski, C, Kiemeney, LA, Massuger, LFAG, van Altena, AM, Aben, KKH, Olson, SH, Orlow, I, Cramer, DW, and Levine, DA et al. "Consortium analysis of gene and gene-folate interactions in purine and pyrimidine metabolism pathways with ovarian carcinoma risk." Molecular nutrition & food research 58, no. 10 (October 2014): 2023-2035.

Full Text

Kokosis, G, Schmitz, R, Secord, A, Havrilesky, L, Berchuck, A, Mantyh, C, and Erdmann, D. "Modifizierter doppelt gestielter VRAM-Lappen zur simultanen Rekonstruktion eines Perineum- und posterioren vaginalen Defekts." Der Gynäkologe 47, no. 10 (October 2014): 784-787.

Full Text

Yamaguchi, K, Huang, Z, Matsumura, N, Mandai, M, Okamoto, T, Baba, T, Konishi, I, Berchuck, A, and Murphy, SK. "Epigenetic determinants of ovarian clear cell carcinoma biology." International Journal of Cancer 135, no. 3 (August 1, 2014): 585-597.

Full Text

Pages